Question special
Lead Moderator

In the supplementary appendix, there was a section describing the incidence of anti-liraglutide antibodies which states that 2.7% exposed patients who had a post-baseline antibody measurement and who did not continue in the 2-year trial extension developed anti-liraglutide antibodies. Is this something that needs to be checked routinely in clinical practice and what is the impact on response to the drug? What about the results for the development of the antibodies during the 12 weeks phase after re-randomization?